BioSpace News Archive

Pliant Therapeutics, Inc. today announced that it presented Phase 2a clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2023 International Conference, held from May 19 through May 24, 2023.

Eloxx Pharmaceuticals, Inc. today announced that the company intends to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations, following the achievement of remission in one patient in its Phase 2 clinical study.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Jefferies Healthcare Conference held on June 7, 2023 in New York City.

Adaptive Phage Therapeutics is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.

Celcuity Inc. today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following investor conferences.

Dermata Therapeutics, Inc. today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 800,877 shares of its common stock.

Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences.

TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers.

Sinaptica Therapeutics, Inc announces the appointment of Ken Mariash Jr. as Chief Executive Officer.

GE HealthCare, a leader in breast cancer care technology and diagnostics, has announced that NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent or metastatic breast cancer.